Overview

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Imp

Status:
Terminated
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
The primary objective of this Phase 2 study is to evaluate the safety of open-label 6 g/day Ace-ER in GNEM participants with severe ambulatory impairment.
Phase:
Phase 2
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc